A Phase 3 interventional study of Tenofovir disoproxil fumarate (TDF) and Placebo in Hepatitis B Virus (HBV), sponsored by Gilead Sciences. Completed at 21 sites in 7 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-09-01.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 30th largest by enrollment, is one of 7 that started in 2008, is one of 13 in phase 3, and was the 10th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 7 started in 2008.
This study's enrollment of 106 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 16th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2008, is one of 8 in phase 3, and was the 14th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to evaluate the effectiveness, safety, and tolerability of tenofovir disoproxil fumarate (TDF) in adolescents (aged 12-17 years) with chronic hepatitis B virus (HBV) infection.
The optimal treatment for adolescents with chronic HBV infection is currently unknown. Treatment with interferon alfa, lamivudine, and adefovir dipivoxil in pediatric populations has been shown to be less than optimal. Further, the safety and efficacy of entecavir and telbivudine have not been established in patients \< 16 years of age. A study evaluating TDF in adolescents (ages 12-17) was needed to assess the safety and efficacy of this agent in the treatment of chronic hepatitis B in this patient population. In addition, the study will help to further elucidate the pharmacokinetic (PK) and resistance profiles of TDF. Through their participation, study participants will help generate critical new information to help guide the most optimal treatment of chronic HBV infection in adolescents.
This is a randomized, double-blind study to evaluate the antiviral efficacy, safety, and tolerability of TDF versus placebo in adolescents with chronic HBV infection. TDF treatment-naive participants were randomized in a 1:1 ratio to TDF or placebo. After 72 weeks of blinded treatment, participants were to switch to open-label TDF for an additional 2.5 years of treatment, provided that no safety concerns are identified by the Independent Data Monitoring Committee monitoring the study.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
This study's enrollment of 106 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Browse Hepatitis B, Chronic studies →Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tenofovir disoproxil fumarate (TDF)
Drug: Placebo
TDF administered as a 300-mg tablet once daily
Also known as: Viread®
TDF placebo tablet once daily
Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72
The percentage of participants with HBV DNA \< 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm. In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included.
Time frame: Week 72
Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72
Data were summarized by treatment and age group (grouped by baseline age for analysis). In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192.
Time frame: Baseline to Week 72
Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Weeks 48, 96, 144, and 192
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Weeks 48, 72, 96, 144, and 192
Percentage of Participants With HBV DNA < 400 Copies/mL and Normal ALT at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Weeks 48, 72, 96, 144, and 192
Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Weeks 48, 72, 96, 144, and 192
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Percentage of Participants With HBsAg Seroconversion at Weeks 48, 72, 96, 144, and 192
HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Percentage of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Weeks 48, 96, 144, and 192
The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Weeks 48, 96, 144, and 192
Percentage of Participants With at Least a 6% Decrease From Baseline in Whole Body BMD at Weeks 48, 72, 96, 144, and 192
The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 48
Percent Change From Baseline in Spine BMD at Week 72
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 72
Percent Change From Baseline in Spine BMD at Week 96
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 96
Percent Change From Baseline in Spine BMD at Week 144
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 144
Percent Change From Baseline in Spine BMD at Week 192
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 192
Percent Change From Baseline in Whole Body BMD at Week 48
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 48
Percent Change From Baseline in Whole Body BMD at Week 72
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 72
Percent Change From Baseline in Whole Body BMD at Week 96
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 96
Percent Change From Baseline in Whole Body BMD at Week 144
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 144
Percent Change From Baseline in Whole Body BMD at Week 192
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 192
Change From Baseline in Z-score for Spine BMD at Week 48
To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject's recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject's recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 48
Change From Baseline in Z-score for Spine BMD at Week 72
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 72
Change From Baseline in Z-score for Spine BMD at Week 96
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 96
Change From Baseline in Z-score for Spine BMD at Week 144
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 144
Change From Baseline in Z-score for Spine BMD at Week 192
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 192
Change From Baseline in Z-score for Whole Body BMD at Week 48
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 48
Change From Baseline in Z-score for Whole Body BMD at Week 72
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 72
Change From Baseline in Z-score for Whole Body BMD at Week 96
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 96
Change From Baseline in Z-score for Whole Body BMD at Week 144
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 144
Change From Baseline in Z-score for Whole Body BMD at Week 192
Data were summarized by treatment and age group (grouped by baseline age for analysis).
Time frame: Baseline; Week 192
Number of Participants With Changes in Drug-Resistant Mutations During the Study
The number of participants with changes in drug-resistant mutations during the study was summarized.
Time frame: Baseline through Week 192
Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Loss at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Percentage of Participants Who Were HBeAg-Positive at Baseline and Who Had HBeAg Seroconversion at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Percentage of Participants Who Were HBeAg-Positive at Baseline Who Had HBV DNA < 400 Copies/mL, Normal ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Percentage of Participants With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL and Normalized ALT at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Percentage of Participants Who Were HBeAg-Positive With Abnormal ALT at Baseline Who Had HBV DNA < 400 Copies/mL, Normalized ALT, and HBeAg Loss/Seroconversion at Weeks 48, 72, 96, 144, and 192
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
Time frame: Baseline; Weeks 48, 72, 96, 144, and 192
Participants were enrolled at 3 sites in the United States, 8 sites in Poland, 3 sites in Romania, 2 sites in Bulgaria, 2 sites in France, 2 sites in Spain, and 1 site in Turkey. The first participant was screened on 03 December 2008. The last study visit occurred on 02 December 2015.
| Milestone | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years |
|---|---|---|---|---|
| Started | 10 | 42 | 13 | 41 |
| Completed | 10 | 41 | 13 | 37 |
| Not completed | 0 | 1 | 0 | 4 |
| Withdrew: Investigator's discretion | 0 | 1 | 0 | 2 |
| Withdrew: Per protocol alt elevation | 0 | 0 | 0 | 2 |
| Milestone | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years |
|---|---|---|---|---|
| Started | 10 | 41 | 13 | 39 |
| Completed | 7 | 39 | 12 | 36 |
| Not completed | 3 | 2 | 1 | 3 |
| Withdrew: Safety, tolerability or efficacy reasons | 1 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 1 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 1 |
| Withdrew: Did not meet entrance criteria | 0 | 0 | 0 | 1 |
The percentage of participants with HBV DNA \< 400 copies/mL at Week 72 was summarized by treatment and age group (grouped by baseline age for analysis), using the missing = failure (M = F) analysis with the double-blind efficacy evaluation (DBEE) algorithm. In the M = F analysis method, all missing data were considered as failure to meet the outcome measure threshold. This method was combined with the DBEE algorithm, which included all available data for the double-blind period, and any data for the open-label period were not included; data generated during treatment-free follow-up from subjects who achieved HBsAg loss and entered treatment-free follow-up during double-blind treatment period were included.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72 | 90.0 | 88.1 | 0 | 0 | 88.5 | 0 |
Data were summarized by treatment and age group (grouped by baseline age for analysis). In contrast with what was previously reported in the interim results posting, 1 participant met the primary safety endpoint of at least a 6% decrease from baseline in spine BMD at Week 72, based on the final BMD data analysis. The apparent discrepancy was due to the correction factor applied to the subject-specific BMD calculations performed at the time of the Interim Week 72 clinical study report that could not take into account the actual Week 72 phantom data (ie, calibration test used in longitudinal clinical trials to monitor and adjust for shifts in the dual-energy x-ray absorptiometry (DXA) scanner calibration over time), which were not provided by the site at that time. The correction factor applied to the final analysis has been properly based on all phantom data through the end of Week 72, as well as through the end of Week 192.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percentage of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 90.0 | 85.7 | 0 | 0 | 86.5 | 0 |
| Week 96 | 90.0 | 88.1 | 53.8 | 68.3 | 88.5 | 64.8 |
| Week 144 | 100.0 | 90.5 | 69.2 | 85.4 | 92.3 | 81.5 |
| Week 192 | 90.0 | 85.7 | 76.9 | 73.2 | 86.5 | 74.1 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 70.0 | 76.2 | 30.8 | 26.8 | 75.0 | 27.8 |
| Week 72 | 80.0 | 76.2 | 30.8 | 41.5 | 76.9 | 38.9 |
| Week 96 | 80.0 | 76.2 | 69.2 | 65.9 | 76.9 | 66.7 |
| Week 144 | 60.0 | 71.4 | 69.2 | 75.6 | 69.2 | 74.1 |
| Week 192 | 80.0 | 71.4 | 84.6 | 75.6 | 73.1 | 77.8 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 70.0 | 69.0 | 0 | 0 | 69.2 | 0 |
| Week 72 | 80.0 | 69.0 | 0 | 0 | 71.2 | 0 |
| Week 96 | 80.0 | 73.8 | 46.2 | 51.2 | 75.0 | 50.0 |
| Week 144 | 60.0 | 69.0 | 53.8 | 68.3 | 67.3 | 64.8 |
| Week 192 | 80.0 | 64.3 | 69.2 | 63.4 | 67.3 | 64.8 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 80.0 | 81.0 | 0 | 0 | 80.8 | 0 |
| Week 72 | 90.0 | 83.3 | 0 | 0 | 84.6 | 0 |
| Week 96 | 90.0 | 88.1 | 53.8 | 63.4 | 88.5 | 61.1 |
| Week 144 | 90.0 | 88.1 | 69.2 | 82.9 | 88.5 | 79.6 |
| Week 192 | 90.0 | 83.3 | 76.9 | 73.2 | 84.6 | 74.1 |
Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 72 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
| Week 96 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
| Week 144 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
| Week 192 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Data were summarized by treatment and age group (grouped by baseline age for analysis), using the M = F.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 72 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
| Week 96 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
| Week 144 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
| Week 192 | 0 | 0 | 0 | 0 | 0 | 0 |
The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 96 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
| Week 144 | 0 | 2.4 | 0 | 0 | 1.9 | 0 |
| Week 192 | 0 | 4.8 | 0 | 4.9 | 3.8 | 3.7 |
The percentage of participants reported is the cumulative incidence from baseline to the respective time point. Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 72 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 96 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 144 | 0 | 0 | 0 | 2.4 | 0 | 1.9 |
| Week 192 | 0 | 0 | 0 | 2.4 | 0 | 1.9 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Spine Bone Mineral Density (BMD) at Week 48 | 9.234 ± 3.4782 | 2.114 ± 3.6023 | 9.038 ± 6.6575 | 4.435 ± 4.9091 | 3.510 ± 4.5507 | 5.562 ± 5.6772 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 72 | 11.516 ± 3.8818 | 3.589 ± 4.5633 | 14.131 ± 9.9563 | 6.117 ± 6.0624 | 5.144 ± 5.4291 | 8.080 ± 7.8996 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 96 | 13.811 ± 4.6712 | 4.196 ± 4.8021 | 16.687 ± 10.4359 | 4.272 ± 7.0463 | 6.119 ± 6.1200 | 7.003 ± 9.3658 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 144 | 19.224 ± 8.7594 | 5.289 ± 5.8084 | 21.346 ± 13.4709 | 6.144 ± 8.3286 | 8.133 ± 8.5611 | 9.311 ± 11.3262 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 192 | 23.933 ± 8.5166 | 6.673 ± 7.2870 | 25.036 ± 14.2346 | 6.867 ± 9.3736 | 10.050 ± 10.1637 | 11.212 ± 13.1459 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Whole Body BMD at Week 48 | 5.123 ± 3.8309 | 1.339 ± 1.9324 | 5.470 ± 3.4958 | 3.236 ± 2.8573 | 2.048 ± 2.7830 | 3.817 ± 3.1576 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Whole Body BMD at Week 72 | 7.282 ± 3.9156 | 2.141 ± 2.6284 | 8.480 ± 4.4770 | 4.335 ± 3.4073 | 3.067 ± 3.4819 | 5.391 ± 4.0902 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Whole Body BMD at Week 96 | 8.034 ± 3.4973 | 3.023 ± 3.2063 | 10.056 ± 5.4296 | 4.291 ± 4.3195 | 3.943 ± 3.7730 | 5.675 ± 5.1858 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Whole Body BMD at Week 144 | 10.940 ± 4.8819 | 3.529 ± 3.1734 | 12.638 ± 5.9973 | 4.730 ± 5.2213 | 4.949 ± 4.5753 | 6.505 ± 6.2944 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| percentage change | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Whole Body BMD at Week 192 | 13.923 ± 4.6139 | 4.295 ± 3.7318 | 14.797 ± 6.4993 | 4.549 ± 5.4494 | 6.086 ± 5.4029 | 7.223 ± 7.2666 |
To assess any effect of treatment on growth, Z-scores were used to express the deviation from a reference population for lumbar spine BMD. A Z-score of 0 indicated that a subject was typical of the population for their age, ethnicity, and gender. A negative Z-score indicated that the subject's recorded value was lower than typical for their age, ethnicity, and gender. A positive Z-score indicates that the subject's recorded value was higher than typical for their age, ethnicity, and gender. Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Spine BMD at Week 48 | 0.02 ± 0.247 | -0.10 ± 0.255 | 0.04 ± 0.393 | 0.05 ± 0.322 | -0.08 ± 0.256 | 0.05 ± 0.337 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Spine BMD at Week 72 | -0.10 ± 0.312 | -0.05 ± 0.325 | 0.09 ± 0.498 | 0.10 ± 0.339 | -0.06 ± 0.320 | 0.10 ± 0.378 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Spine BMD at Week 96 | -0.19 ± 0.365 | -0.07 ± 0.356 | -0.02 ± 0.498 | -0.13 ± 0.414 | -0.10 ± 0.357 | -0.11 ± 0.431 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Spine BMD at Week 144 | -0.20 ± 0.560 | -0.05 ± 0.417 | -0.16 ± 0.625 | -0.04 ± 0.405 | -0.08 ± 0.447 | -0.06 ± 0.455 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Spine BMD at Week 192 | -0.24 ± 0.518 | 0.08 ± 0.544 | -0.26 ± 0.654 | -0.05 ± 0.504 | 0.02 ± 0.548 | -0.10 ± 0.543 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Whole Body BMD at Week 48 | 0.02 ± 0.426 | -0.15 ± 0.257 | 0.10 ± 0.370 | 0.04 ± 0.308 | -0.12 ± 0.298 | 0.05 ± 0.322 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Whole Body BMD at Week 72 | 0.02 ± 0.398 | -0.19 ± 0.338 | 0.20 ± 0.450 | 0.06 ± 0.306 | -0.16 ± 0.355 | 0.09 ± 0.349 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Whole Body BMD at Week 96 | -0.12 ± 0.294 | -0.19 ± 0.451 | 0.09 ± 0.528 | -0.06 ± 0.432 | -0.18 ± 0.424 | -0.03 ± 0.456 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Whole Body BMD at Week 144 | -0.27 ± 0.431 | -0.21 ± 0.473 | -0.06 ± 0.554 | -0.16 ± 0.468 | -0.22 ± 0.462 | -0.14 ± 0.484 |
Data were summarized by treatment and age group (grouped by baseline age for analysis).
| z-score | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Change From Baseline in Z-score for Whole Body BMD at Week 192 | -0.34 ± 0.499 | -0.11 ± 0.524 | -0.21 ± 0.486 | -0.19 ± 0.517 | -0.16 ± 0.521 | -0.19 ± 0.504 |
The number of participants with changes in drug-resistant mutations during the study was summarized.
| participants | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|
| New TDF Drug-Resistant Mutations | 0 | 0 |
| Enrichment of TDF Drug-Resistant Mutations | 0 | 0 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 11.1 | 17.9 | 7.7 | 8.6 | 16.7 | 8.3 |
| Week 72 | 11.1 | 23.1 | 23.1 | 11.4 | 20.8 | 14.6 |
| Week 96 | 44.4 | 30.8 | 38.5 | 28.6 | 33.3 | 31.3 |
| Week 144 | 44.4 | 38.5 | 53.8 | 34.3 | 39.6 | 39.6 |
| Week 192 | 33.3 | 43.6 | 53.8 | 37.1 | 41.7 | 41.7 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 11.1 | 15.4 | 7.7 | 8.6 | 14.6 | 8.3 |
| Week 72 | 11.1 | 23.1 | 23.1 | 11.4 | 20.8 | 14.6 |
| Week 96 | 44.4 | 30.8 | 38.5 | 25.7 | 33.3 | 29.2 |
| Week 144 | 33.3 | 38.5 | 53.8 | 34.3 | 37.5 | 39.6 |
| Week 192 | 33.3 | 38.5 | 53.8 | 37.1 | 37.5 | 41.7 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 11.1 | 12.8 | 0 | 0 | 12.5 | 0 |
| Week 72 | 11.1 | 15.4 | 0 | 0 | 14.6 | 0 |
| Week 96 | 44.4 | 28.2 | 30.8 | 22.9 | 31.3 | 25.0 |
| Week 144 | 22.2 | 30.8 | 46.2 | 25.7 | 29.2 | 31.3 |
| Week 192 | 33.3 | 28.2 | 46.2 | 25.7 | 29.2 | 31.3 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 85.7 | 71.4 | 11.1 | 21.2 | 74.3 | 19.0 |
| Week 72 | 85.7 | 71.4 | 22.2 | 33.3 | 74.3 | 31.0 |
| Week 96 | 85.7 | 78.6 | 66.7 | 63.6 | 80.0 | 64.3 |
| Week 144 | 57.1 | 71.4 | 66.7 | 72.7 | 68.6 | 71.4 |
| Week 192 | 85.7 | 75.0 | 77.8 | 69.7 | 77.1 | 71.4 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 85.7 | 71.4 | 0 | 0 | 74.3 | 0 |
| Week 72 | 85.7 | 71.4 | 0 | 0 | 74.3 | 0 |
| Week 96 | 85.7 | 78.6 | 55.6 | 54.5 | 80.0 | 54.8 |
| Week 144 | 57.1 | 71.4 | 66.7 | 69.7 | 68.6 | 69.0 |
| Week 192 | 85.7 | 67.9 | 77.8 | 57.6 | 71.4 | 61.9 |
Data were summarized by treatment and age group (grouped by baseline age for analysis) using the missing = failure method.
| percentage of participants | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total TDF 12-17 Years | Total Placebo 12-17 Years |
|---|---|---|---|---|---|---|
| Week 48 | 16.7 | 18.5 | 0 | 0 | 18.2 | 0 |
| Week 72 | 16.7 | 22.2 | 0 | 0 | 21.2 | 0 |
| Week 96 | 50.0 | 33.3 | 33.3 | 24.2 | 36.4 | 26.2 |
| Week 144 | 33.3 | 29.6 | 55.6 | 27.3 | 30.3 | 33.3 |
| Week 192 | 50.0 | 29.6 | 55.6 | 27.3 | 33.3 | 33.3 |
Collected over Baseline through end of the Open-Label Phase (up to 4 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind TDF | — | 5/52 (9.6%) | 34/52 (65.4%) |
| Double-Blind Placebo | — | 11/54 (20.4%) | 40/54 (74.1%) |
| Open-Label TDF-TDF | — | 8/51 (15.7%) | 30/51 (58.8%) |
| Open-Label Placebo-TDF | — | 10/52 (19.2%) | 31/52 (59.6%) |
| Event | Double-Blind TDF | Double-Blind Placebo | Open-Label TDF-TDF | Open-Label Placebo-TDF |
|---|---|---|---|---|
| HepatitisHepatobiliary disorders | 1/52 | 7/54 | 1/51 | 0/52 |
| Alanine aminotransferase increasedInvestigations | 0/52 | 1/54 | 0/51 | 3/52 |
| Ventricular extrasystolesCardiac disorders | 0/52 | 0/54 | 1/51 | 0/52 |
| Abdominal painGastrointestinal disorders | 0/52 | 1/54 | 1/51 | 1/52 |
| Peptic ulcer perforationGastrointestinal disorders | 0/52 | 0/54 | 1/51 | 0/52 |
| Patella fractureInjury, poisoning and procedural complications | 0/52 | 0/54 | 1/51 | 0/52 |
| Blood creatinine increasedInvestigations | 0/52 | 0/54 | 1/51 | 0/52 |
| Glucose urine presentInvestigations | 0/52 | 0/54 | 1/51 | 0/52 |
| Protein urine presentInvestigations | 0/52 | 0/54 | 1/51 | 0/52 |
| DepressionPsychiatric disorders | 0/52 | 0/54 | 1/51 | 0/52 |
| Event | Double-Blind TDF | Double-Blind Placebo | Open-Label TDF-TDF | Open-Label Placebo-TDF |
|---|---|---|---|---|
| PharyngitisInfections and infestations | 15/52 | 11/54 | 9/51 | 13/52 |
| NasopharyngitisInfections and infestations | 5/52 | 12/54 | 6/51 | 12/52 |
| AcneSkin and subcutaneous tissue disorders | 2/52 | 10/54 | 2/51 | 6/52 |
| Abdominal painGastrointestinal disorders | 3/52 | 7/54 | 1/51 | 9/52 |
| HeadacheNervous system disorders | 2/52 | 9/54 | 1/51 | 2/52 |
| Upper respiratory tract infectionInfections and infestations | 5/52 | 7/54 | 3/51 | 7/52 |
| BronchitisInfections and infestations | 2/52 | 1/54 | 6/51 | 4/52 |
| GastroenteritisInfections and infestations | 2/52 | 2/54 | 0/51 | 5/52 |
| RhinitisInfections and infestations | 5/52 | 3/54 | 3/51 | 1/52 |
| LymphadenopathyBlood and lymphatic system disorders | 0/52 | 5/54 | 1/51 | 0/52 |
| Age, Continuous(years) | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total |
|---|---|---|---|---|---|
| Mean | 13.3 ± 0.82 | 16.1 ± 0.75 | 13.2 ± 0.69 | 15.9 ± 0.82 | 15.4 ± 1.38 |
| Sex: Female, Male(Participants) | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total |
|---|---|---|---|---|---|
| Female | 3 | 11 | 4 | 15 | 33 |
| Male | 7 | 31 | 9 | 26 | 73 |
| Race/Ethnicity, Customized(participants) | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total |
|---|---|---|---|---|---|
| Asian | 0 | 1 | 1 | 0 | 2 |
| Black | 0 | 1 | 0 | 0 | 1 |
| White | 10 | 39 | 12 | 37 | 98 |
| Other | 0 | 1 | 0 | 4 | 5 |
| Region of Enrollment(participants) | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total |
|---|---|---|---|---|---|
| Bulgaria | 0 | 3 | 3 | 1 | 7 |
| France | 0 | 1 | 0 | 1 | 2 |
| Poland | 6 | 31 | 6 | 31 | 74 |
| Romania | 4 | 4 | 2 | 4 | 14 |
| Spain | 0 | 0 | 0 | 2 | 2 |
| Turkey | 0 | 1 | 1 | 0 | 2 |
| United States | 0 | 2 | 1 | 2 | 5 |
| Region of Enrollment(participants) | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total |
|---|---|---|---|---|---|
| Europe | 10 | 40 | 12 | 39 | 101 |
| North America | 0 | 2 | 1 | 2 | 5 |
| Alanine aminotransferase (ALT) level at baseline(U/L) | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total |
|---|---|---|---|---|---|
| Mean | 77 ± 54.8 | 106 ± 116.4 | 101 ± 95.4 | 101 ± 89.5 | 101 ± 98.5 |
| ALT normal at baseline(participants) | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total |
|---|---|---|---|---|---|
| Normal | 3 | 14 | 4 | 8 | 29 |
| Abnormal | 7 | 28 | 9 | 33 | 77 |
| HBV Genotype(participants) | TDF 12-14 Years | TDF 15-17 Years | Placebo 12-14 Years | Placebo 15-17 Years | Total |
|---|---|---|---|---|---|
| Genotype A | 5 | 30 | 5 | 29 | 69 |
| Genotype B | 0 | 1 | 1 | 1 | 3 |
| Genotype C | 0 | 1 | 0 | 0 | 1 |
| Genotype D | 5 | 10 | 7 | 11 | 33 |
2 further baseline measures are reported on the registry.
The record gives a start of Dec 2008, a primary completion of Mar 2011 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 8 months after primary completion. A results delay was requested in Apr 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir